Differential in vitro anti-leukemic activity of resveratrol combined with serine palmitoyltransferase inhibitor myriocin in FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) carrying AML cells

dc.contributor.author Ersoz, Nur Sebnem
dc.contributor.author Adan, Aysun
dc.contributor.authorID 0000-0003-3343-9936 en_US
dc.contributor.authorID 0000-0002-3747-8580 en_US
dc.contributor.department AGÜ, Yaşam ve Doğa Bilimleri Fakültesi, Moleküler Biyoloji ve Genetik Bölümü en_US
dc.contributor.institutionauthor Ersoz, Nur Sebnem
dc.contributor.institutionauthor Adan, Aysun
dc.date.accessioned 2023-04-05T07:03:00Z
dc.date.available 2023-04-05T07:03:00Z
dc.date.issued 2022 en_US
dc.description.abstract Treatment of FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) AML is restricted due to toxicity, drug resistance and relapse eventhough targeted therapies are clinically available. Resveratrol with its multi-targeted nature is a promising chemopreventive remaining limitedly studied in FLT3-ITD AML regarding to ceramide metabolism. Here, its cytotoxic, cytostatic and apoptotic effects are investigated in combination with serine palmitoyltransferase (SPT), the first enzyme of de novo pathway of ceramide production, inhibitor myriocin on MOLM-13 and MV4-11 cells. We assessed dose-dependent cell viability, flow cytometric cell death and cell cycle profiles of resveratrol in combination with myriocin by MTT assay, annexin-V/PI staining and PI staining respectively. Resveratrol's dose-dependent effect on SPT protein expression was also checked by western blot. Resveratrol decreased cell viability in a dose- dependent manner whereas myriocin did not affect cell proliferation effectively in both cell lines after 48h treatments. Although resveratrol induced both apoptosis and a significant S phase arrest in MV4-11 cells, it triggered apoptosis and non-significant S phase accumulation in MOLM-13 cells. Co-administrations reduced cell viability. Increased cytotoxic effect of co-treatments was further proved mechanistically through induction of apoptosis via phosphatidylserine relocalization. The cell cycle alteration in co-treatment was significant with an S phase arrest in MV4-11 cells, however, it was not effective on cell cycle progression of MOLM-13 cells. Resveratrol also increased SPT expression. Overall, modulation of SPT together with resveratrol might be the possible explanation for resveratrol's action. It could be an integrative medicine for FLT3-ITD AML after investigating its detailed mechanism of action in relation to de novo pathway of ceramide production. en_US
dc.description.sponsorship Abdullah Gul University Scientific Research Projects Coordination Unit FAB-2016-66 en_US
dc.identifier.endpage 281 en_US
dc.identifier.issn 0920-9069
dc.identifier.issn 1573-0778
dc.identifier.issue 2 en_US
dc.identifier.other WOS:000754931800001
dc.identifier.startpage 271 en_US
dc.identifier.uri https://doi.org/10.1007/s10616-022-00527-1
dc.identifier.uri https://hdl.handle.net/20.500.12573/1560
dc.identifier.volume 74 en_US
dc.language.iso eng en_US
dc.publisher SPRINGER en_US
dc.relation.isversionof 10.1007/s10616-022-00527-1 en_US
dc.relation.journal CYTOTECHNOLOGY en_US
dc.relation.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.subject Apoptosis en_US
dc.subject Cell cycle en_US
dc.subject FLT3-ITD AML en_US
dc.subject Resveratrol en_US
dc.subject Serine palmitoyltransferase en_US
dc.title Differential in vitro anti-leukemic activity of resveratrol combined with serine palmitoyltransferase inhibitor myriocin in FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) carrying AML cells en_US
dc.type article en_US

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
s10616-022-00527-1.pdf
Size:
3.14 MB
Format:
Adobe Portable Document Format
Description:
Makale Dosyası

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.44 KB
Format:
Item-specific license agreed upon to submission
Description: